The trial is now scheduled to begin remotely starting
About
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include RYANODEX, BENDEKA, BELRAPZO, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as 'anticipated,' 'forward,' 'will,' 'would,' 'may,' 'remain,' 'potential,' 'prepare,' 'expected,' 'believe,' 'plan,' 'near future,' 'belief,' 'guidance,' and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the status and timing of pending or future litigation. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic, including further disruption or delay of any pending or future litigation, and those risks and uncertainties identified in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended
Contact:
Tel: 212-452-2793
Email: lwilson@insitecony.com
(C) 2021 Electronic News Publishing, source